Previous 10 | Next 10 |
Gainers: Intra-Cellular Therapies (NASDAQ: ITCI ) +204% . More news on: Intra-Cellular Therapies, Inc., Cassava Sciences, Inc., Microbot Medical Inc., Stocks on the move, Read more ...
Paratek Pharmaceuticals (NASDAQ: PRTK ) +45% on BARDA contract for Nuzyra. More news on: Paratek Pharmaceuticals, Inc., Rite Aid Corporation, Catalyst Biosciences, Inc., Stocks on the move, Read more ...
Gainers: REVG +6.9% . MU +3.4% . PCG +2.2% . OBSV +2.8% . DERM +1.1% . More news on: REV Group, Inc., Micron Technology, Inc., PG&E Corporation, Stocks on the move, , News on ETFs Read more ...
Gainers: ASLN +8.6% . NK +7.1% . SCS +5.5% . OBSV +2.8% . CTAS +2.8% . More news on: ASLAN Pharmaceuticals Limited, NantKwest, Inc., Steelcase Inc., Stocks on the move, , News on ETFs Read more ...
Technical Communications (NASDAQ: TCCO ) +260% after Q4 results . More news on: Technical Communications Corporation, Equillium, Inc., CounterPath Corporation, Stocks on the move, Read more ...
Gainers: Synthorx (NASDAQ: THOR ) +170% . More news on: Synthorx, Inc., ArQule, Inc., Forty Seven, Inc., Stocks on the move, Read more ...
Synthorx (NASDAQ: THOR ) +169% on being acquired by Sanofi. More news on: Synthorx, Inc., XBiotech Inc., ArQule, Inc., Stocks on the move, Read more ...
ObsEva SA (NASDAQ: OBSV ) is up 26% premarket on the heels of positive results from a Phase 3 PRIMROSE 2 trial evaluating linzagolix, including 100 mg and 200 mg doses, both with and without hormonal add-back therapy (ABT) for the treatment of heavy menstrual bleeding...
Phase 3 trial (PRIMROSE 2) met primary and secondary efficacy endpoints 93.9% responder rate for 200 mg with ABT (p < 0.001) 56.7% responder rate for 100 mg without ABT (p < 0.001) Both doses achieved important clinically relevant secondary endpoints including amenorrhea (p &l...
The following list reflects actual dividend paying stocks that I hold in my personal portfolio: Barings BDC, Inc. ( BBDC ), BlackRock Capital Investment ( BKCC ), Blueknight Energy Partners - PFD Units ( BKEPP ), BlackRock Income Trust ( BKT ), BlackRock Enhanced Equity Dividend Trust ( BDJ ),...
News, Short Squeeze, Breakout and More Instantly...
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – April 3, 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that the Regulatory ...
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 18, 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that, concurr...
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – 28 February 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's health, today announced that it will wind-down its operati...